The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. For all confirmed or suspected cases of COVID-19, data about concomitant disease, ongoing therapies, and comorbidities were also reported. Results A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort twenty-six patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. 125 of 12807 patients (1.0%) with exposure to a patient with COVID-19 under quarantine or active health surveillance, were reported. Conclusion The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen “cytokine storm” of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. Risk analysis from the PSO-BIO-COVID observational study / Talamonti, M; Galluzzo, M; Chiricozzi, A; Quaglino, P; Fabbrocini, G; Gisondi, P; Marzano, Av; Potenza, C; Conti, A; Parodi, A; Belloni Fortina, A; Bardazzi, F; Argenziano, G; Rongioletti, F; Stingeni, L; Micali, G; Loconsole, F; Venturini, M; Bongiorno, Mr; Feliciani, C; Rubegni, P; Amerio, P; Fargnoli, Mc; Pigatto, P; Savoia, P; Nisticò, Sp; Giustini, S; Carugno, A; Cannavò, Sp; Rech, G; Prignano, F; Offidani, A; Lombardo, M; Zalaudek, I; Bianchi, L; Peris, K; PSO-BIO-COVID study, Group.. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1744-7682. - 21:2(2021), pp. 271-277. [10.1080/14712598.2021.1853698]

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. Risk analysis from the PSO-BIO-COVID observational study

Potenza C;Giustini S;
2021

Abstract

The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. For all confirmed or suspected cases of COVID-19, data about concomitant disease, ongoing therapies, and comorbidities were also reported. Results A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort twenty-six patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. 125 of 12807 patients (1.0%) with exposure to a patient with COVID-19 under quarantine or active health surveillance, were reported. Conclusion The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen “cytokine storm” of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death
File allegati a questo prodotto
File Dimensione Formato  
Talamonti_postprint_Characteristic-chronic-plaque_2021.pdf

embargo fino al 14/01/2022

Note: https://www.tandfonline.com/doi/full/10.1080/14712598.2021.1853698
Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 745.24 kB
Formato Adobe PDF
745.24 kB Adobe PDF Visualizza/Apri PDF
Talamonti_Characteristic-chronic-plaque_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 565.37 kB
Formato Adobe PDF
565.37 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/1570778
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 26
social impact